Antithymocyte Globulin (ATG) and Cyclosporine (CSA) to Treat Patients With Myelodysplastic Syndrome (MDS). A Randomized Trial Comparing ATG + CSA With Best Supportive Care
This trial will answer the question whether immuno-suppression improves hematopoesis and
reduces transfusion requirements analogous to patients with aplastic anemia as the
short-term outcome, and whether immuno-suppression accelerates leukemic transformation and
influences survival as the long-term outcome.
Primary endpoint: best response (CR + PR) rate at month 6
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Best response rate (CR + PR)
6 months
No
Jakob R. Passweg, MS
Study Chair
Kantonsspital Basel
Switzerland: Swissmedic
SAKK 33/99
NCT00004208
August 2000
October 2011
Name | Location |
---|